메뉴 건너뛰기




Volumn 121, Issue 5, 2009, Pages 94-107

The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus

Author keywords

Cardiovascular disease; Exenatide; Incretin therapy; Obesity; Type 2 diabetes mellitus; Weight gain

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALOGLIPTIN; ANTIDIABETIC AGENT; BIPHASIC INSULIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN SENSITIZING AGENT; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

EID: 77954189321     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.09.2056     Document Type: Review
Times cited : (74)

References (86)
  • 2
    • 11844253332 scopus 로고    scopus 로고
    • Prevalence of overweight and obesity among adults with diagnosed diabetes - United States, 1988-1994 and 1999-2002
    • Centers for Disease Control and Prevention
    • Centers for Disease Control and Prevention. Prevalence of overweight and obesity among adults with diagnosed diabetes - United States, 1988-1994 and 1999-2002. Morb Mortal Wkly Rep. 2004;53(45):1066-1068.
    • (2004) Morb Mortal Wkly Rep , vol.53 , Issue.45 , pp. 1066-1068
  • 4
    • 58049219012 scopus 로고    scopus 로고
    • Adipose tissue dysfunction in obesity, diabetes, and vascular diseases
    • Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959-2971.
    • (2008) Eur Heart J , vol.29 , Issue.24 , pp. 2959-2971
    • Hajer, G.R.1    Van Haeften, T.W.2    Visseren, F.L.3
  • 5
    • 27644457743 scopus 로고    scopus 로고
    • Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study
    • INTERHEART Study Investigators
    • Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640-1649.
    • (2005) Lancet , vol.366 , Issue.9497 , pp. 1640-1649
    • Yusuf, S.1    Hawken, S.2    Ounpuu, S.3
  • 6
    • 54049111104 scopus 로고    scopus 로고
    • The effects of pharmacologic agents for type 2 diabetes mellitus on body weight
    • Pi-Sunyer FX. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med. 2008;120(2):5-17.
    • (2008) Postgrad Med , vol.120 , Issue.2 , pp. 5-17
    • Pi-Sunyer, F.X.1
  • 8
    • 49649083150 scopus 로고    scopus 로고
    • Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study
    • Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008;31(8):1582-1584.
    • (2008) Diabetes Care , vol.31 , Issue.8 , pp. 1582-1584
    • Fox, C.S.1    Pencina, M.J.2    Wilson, P.W.3    Paynter, N.P.4    Vasan, R.S.5    D'Agostino Sr., R.B.6
  • 9
    • 0020533259 scopus 로고
    • Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study
    • Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-977. (Pubitemid 13080473)
    • (1983) Circulation , vol.67 , Issue.5 , pp. 968-977
    • Hubert, H.B.1    Feinleib, M.2    McNamara, P.M.3    Castelli, W.P.4
  • 10
    • 0141988862 scopus 로고    scopus 로고
    • Importance of weight management in type 2 diabetes: Review with meta-analysis of clinical studies
    • Anderson JW, Kendall CW, Jenkins DJA. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutrition. 2003;22(5):331-339.
    • (2003) J Am Coll Nutrition , vol.22 , Issue.5 , pp. 331-339
    • Anderson, J.W.1    Kendall, C.W.2    Jenkins, D.J.A.3
  • 11
    • 57249103368 scopus 로고    scopus 로고
    • Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: An observational study in 13,087 patients
    • Eeg-Olofsson K, Cederhohn J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65-73.
    • (2009) Diabetologia , vol.52 , Issue.1 , pp. 65-73
    • Eeg-Olofsson, K.1    Cederhohn, J.2    Nilsson, P.M.3
  • 12
    • 24944482507 scopus 로고    scopus 로고
    • The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: A prospective epidemiological analysis
    • Gerstein HC, Pogue J, Mann JFE, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 2005;48(9):1749-1755.
    • (2005) Diabetologia , vol.48 , Issue.9 , pp. 1749-1755
    • Gerstein, H.C.1    Pogue, J.2    Mann, J.F.E.3
  • 13
    • 0034641568 scopus 로고    scopus 로고
    • Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
    • Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
    • (2000) BMJ , vol.321 , Issue.7258 , pp. 405-412
    • Stratton, I.M.1    Adler, A.I.2    Neil, H.A.3
  • 14
    • 63149103614 scopus 로고    scopus 로고
    • Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
    • Skyler JS, Bergenstal R, Bonow R, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187-192.
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 187-192
    • Skyler, J.S.1    Bergenstal, R.2    Bonow, R.3
  • 15
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131): 837-853.
    • (1998) Lancet , vol.352 , Issue.9131 , pp. 837-853
  • 16
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering in type 2 diabetes
    • Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group
    • Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
    • (2008) N Engl J Med , vol.358 , Issue.24 , pp. 2545-2559
    • Gerstein, H.C.1    Miller, M.E.2    Byington, R.P.3
  • 18
    • 56149117155 scopus 로고    scopus 로고
    • Glycemic control in diabetes: A tale of three studies
    • Bloomgarden ZT. Glycemic control in diabetes: a tale of three studies. Diabetes Care. 2008;31(9):1913-1919.
    • (2008) Diabetes Care , vol.31 , Issue.9 , pp. 1913-1919
    • Bloomgarden, Z.T.1
  • 19
    • 45149118855 scopus 로고    scopus 로고
    • Intensive glycemic control in the ACCORD and ADVANCE trials
    • Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358(24):2630-2633.
    • (2008) N Engl J Med , vol.358 , Issue.24 , pp. 2630-2633
    • Dluhy, R.G.1    McMahon, G.T.2
  • 20
    • 34249864128 scopus 로고    scopus 로고
    • Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the look AHEAD trial
    • Look AHEAD Research Group
    • Look AHEAD Research Group; Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374-1383.
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1374-1383
    • Pi-Sunyer, X.1    Blackburn, G.2    Brancati, F.L.3
  • 21
    • 0032511580 scopus 로고    scopus 로고
    • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
    • (1998) BMJ , vol.317 , Issue.7160 , pp. 703-713
  • 23
    • 37349010670 scopus 로고    scopus 로고
    • Medical guidelines for clinical practice for the management of diabetes mellitus
    • American Association of Clinical Endocrinologists Clinical Practice Guidelines Task Force
    • American Association of Clinical Endocrinologists Clinical Practice Guidelines Task Force. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1-68.
    • (2007) Endocr Pract , vol.13 , Issue.SUPPL. 1 , pp. 1-68
  • 24
    • 40349108600 scopus 로고    scopus 로고
    • Nutrition recommendations and interventions for diabetes: A position statement of the American Diabetes Association
    • American Diabetes Association
    • American Diabetes Association; Bantle JP, Wylie-Rosett J, Albright AL, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31(Suppl 1):S61-S78.
    • (2008) Diabetes Care , vol.31 , Issue.SUPPL. 1
    • Bantle, J.P.1    Wylie-Rosett, J.2    Albright, A.L.3
  • 25
    • 63149173251 scopus 로고    scopus 로고
    • Standards of medical care in diabetes - 2009
    • American Diabetes Association
    • American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.
    • (2009) Diabetes Care , vol.32 , Issue.SUPPL. 1
  • 26
    • 3343024281 scopus 로고    scopus 로고
    • Weight management through lifestyle modification for the prevention and management of type 2 diabetes: Rationale and strategies: A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition
    • Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27(8):2067-2073.
    • (2004) Diabetes Care , vol.27 , Issue.8 , pp. 2067-2073
    • Klein, S.1    Sheard, N.F.2    Pi-Sunyer, X.3
  • 27
    • 0029966681 scopus 로고    scopus 로고
    • Weight and non-insulin-dependent diabetes mellitus
    • Pi-Sunyer FX. Weight and non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1996;63(3 Suppl):426S-429S.
    • (1996) Am J Clin Nutr , vol.63 , Issue.3 SUPPL.
    • Pi-Sunyer, F.X.1
  • 28
    • 0036479806 scopus 로고    scopus 로고
    • Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding
    • Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care. 2002;25(2):358-363.
    • (2002) Diabetes Care , vol.25 , Issue.2 , pp. 358-363
    • Dixon, J.B.1    O'Brien, P.E.2
  • 29
    • 19944380155 scopus 로고    scopus 로고
    • Weight loss in type 2 diabetic patients
    • DOI 10.2337/diacare.28.6.1526
    • Pi-Sunyer FX. Weight loss in type 2 diabetic patients. Diabetes Care. 2005;28(6):1526-1527. (Pubitemid 40756731)
    • (2005) Diabetes Care , vol.28 , Issue.6 , pp. 1526-1527
    • Pi-Sunyer, F.X.1
  • 30
    • 64749100501 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • American Diabetes Association; European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 31
    • 21844434480 scopus 로고    scopus 로고
    • Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus
    • Apr 18; CD003638
    • Vermeire E, Wens J, Van Royen P, Biot Y, Hearnshaw H, Lindenmeyer A. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003638.
    • (2005) Cochrane Database Syst Rev , Issue.2
    • Vermeire, E.1    Wens, J.2    Van Royen, P.3    Biot, Y.4    Hearnshaw, H.5    Lindenmeyer, A.6
  • 32
    • 33646264519 scopus 로고    scopus 로고
    • Improving patient adherence
    • Delamater AM. Improving patient adherence. Clin Diabetes. 2006;24(2):71-77.
    • (2006) Clin Diabetes , vol.24 , Issue.2 , pp. 71-77
    • Delamater, A.M.1
  • 33
    • 67049155777 scopus 로고    scopus 로고
    • An assessment of attitudes, behaviors, and outcomes of patients with type 2 diabetes
    • Daly JM, Hartz AJ, Xu Y, et al. An assessment of attitudes, behaviors, and outcomes of patients with type 2 diabetes. J Am Board Fam Med. 2009;22(3):280-290.
    • (2009) J Am Board Fam Med , vol.22 , Issue.3 , pp. 280-290
    • Daly, J.M.1    Hartz, A.J.2    Xu, Y.3
  • 34
    • 77649222023 scopus 로고    scopus 로고
    • General practitioners trained in motivational interviewing can positively affect the attitude to behaviour change in people with type 2 diabetes
    • Rubak S, Sandbaek A, Lauritzen T, Borch-Johnsen K, Christensen B. General practitioners trained in motivational interviewing can positively affect the attitude to behaviour change in people with type 2 diabetes. Scand J Prim Health Care. 2009;29:1-8.
    • (2009) Scand J Prim Health Care , vol.29 , pp. 1-8
    • Rubak, S.1    Sandbaek, A.2    Lauritzen, T.3    Borch-Johnsen, K.4    Christensen, B.5
  • 35
    • 37549007554 scopus 로고    scopus 로고
    • The impact of apathy on glycemic control in diabetes: A cross-sectional study
    • Padala PR, Desouza CV, Almeida S, et al. The impact of apathy on glycemic control in diabetes: a cross-sectional study. Diabetes Res Clin Pract. 2008;79(1):37-41.
    • (2008) Diabetes Res Clin Pract , vol.79 , Issue.1 , pp. 37-41
    • Padala, P.R.1    Desouza, C.V.2    Almeida, S.3
  • 36
    • 0031702682 scopus 로고    scopus 로고
    • Supporting autonomy to motivate patients with diabetes for glucose control
    • Williams GC, Freedman ZR, Deci EL. Supporting autonomy to motivate patients with diabetes for glucose control. Diabetes Care. 1998;21(10):1644- 1651.
    • (1998) Diabetes Care , vol.21 , Issue.10 , pp. 1644-1651
    • Williams, G.C.1    Freedman, Z.R.2    Deci, E.L.3
  • 37
    • 15944403259 scopus 로고    scopus 로고
    • Variation in perceived competence, glycemic control, and patient satisfaction: Relationship to autonomy support from physicians
    • Williams GC, McGregor HA, King D, Nelson CC, Glasgow RE. Variation in perceived competence, glycemic control, and patient satisfaction: relationship to autonomy support from physicians. Patient Educ Courts. 2005;57(1):39-45.
    • (2005) Patient Educ Courts , vol.57 , Issue.1 , pp. 39-45
    • Williams, G.C.1    McGregor, H.A.2    King, D.3    Nelson, C.C.4    Glasgow, R.E.5
  • 38
    • 20444493790 scopus 로고    scopus 로고
    • Psychosocial problems and barriers to improved diabetes management: Results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study
    • Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Med. 2005;22(10):1379-1385.
    • (2005) Diabetes Med , vol.22 , Issue.10 , pp. 1379-1385
    • Peyrot, M.1    Rubin, R.R.2    Lauritzen, T.3    Snoek, F.J.4    Matthews, D.R.5    Skovlund, S.E.6
  • 40
    • 33847634381 scopus 로고    scopus 로고
    • Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: Lessons learned from a clinical trial comparing biphasic and basal analogues
    • DOI 10.1186/1477-7525-5-8
    • Brod M, Cobden D, Lammert M, Bushnell D, Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes. 2007;5:8. (Pubitemid 46351119)
    • (2007) Health and Quality of Life Outcomes , vol.5 , pp. 8
    • Brod, M.1    Cobden, D.2    Lammert, M.3    Bushnell, D.4    Raskin, P.5
  • 41
    • 36349035961 scopus 로고    scopus 로고
    • Adherence, body mass index, and depression in adults with type 2 diabetes: The mediational role of diabetes symptoms and self-efficacy
    • Sacco WP, Wells KJ, Friedman A, Matthew R, Perez S, Vaughan CA. Adherence, body mass index, and depression in adults with type 2 diabetes: the mediational role of diabetes symptoms and self-efficacy. Health Psychol. 2007;26(6):693-700.
    • (2007) Health Psychol , vol.26 , Issue.6 , pp. 693-700
    • Sacco, W.P.1    Wells, K.J.2    Friedman, A.3    Matthew, R.4    Perez, S.5    Vaughan, C.A.6
  • 42
    • 35048841093 scopus 로고    scopus 로고
    • Insulin-associated weight gain in diabetes - Causes, effects and coping strategies
    • Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabetes Obes Metab. 2007;9(6):799-812.
    • (2007) Diabetes Obes Metab , vol.9 , Issue.6 , pp. 799-812
    • Russell-Jones, D.1    Khan, R.2
  • 43
    • 34447300177 scopus 로고    scopus 로고
    • Weight gain as an adverse effect of some commonly prescribed drugs: A systematic review
    • Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. Q J Med. 2007;100(7):395-404.
    • (2007) Q J Med , vol.100 , Issue.7 , pp. 395-404
    • Leslie, W.S.1    Hankey, C.R.2    Lean, M.E.3
  • 44
    • 0042861368 scopus 로고    scopus 로고
    • Weight effect of current and experimental drugs for diabetes mellitus: From promotion to alleviation of obesity
    • Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol. 2003;2(1):33-47.
    • (2003) Treat Endocrinol , vol.2 , Issue.1 , pp. 33-47
    • Purnell, J.Q.1    Weyer, C.2
  • 45
    • 33750726976 scopus 로고    scopus 로고
    • Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
    • Secnik Boye K, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes. 2006;4:80.
    • (2006) Health Qual Life Outcomes , vol.4 , pp. 80
    • Secnik Boye, K.1    Matza, L.S.2    Oglesby, A.3
  • 46
    • 33845472504 scopus 로고    scopus 로고
    • Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    • Sitagliptin Study 021 Group
    • Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-2637.
    • (2006) Diabetes Care , vol.29 , Issue.12 , pp. 2632-2637
    • Aschner, P.1    Kipnes, M.S.2    Lunceford, J.K.3    Sanchez, M.4    Mickel, C.5    Williams-Herman, D.E.6
  • 47
    • 55549136417 scopus 로고    scopus 로고
    • Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study
    • DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943-2952.
    • (2008) Curr Med Res Opin , vol.24 , Issue.10 , pp. 2943-2952
    • DeFronzo, R.A.1    Okerson, T.2    Viswanathan, P.3    Guan, X.4    Holcombe, J.H.5    MacConell, L.6
  • 48
    • 59449101432 scopus 로고    scopus 로고
    • Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial
    • LEAD-3 (Mono) Study Group
    • Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-481.
    • (2009) Lancet , vol.373 , Issue.9662 , pp. 473-481
    • Garber, A.1    Henry, R.2    Ratner, R.3
  • 49
    • 49649103582 scopus 로고    scopus 로고
    • Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes
    • Kawai T, Funae O, Shimada A, et al. Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. Intern Med. 2008;47(13):1181-1188.
    • (2008) Intern Med , vol.47 , Issue.13 , pp. 1181-1188
    • Kawai, T.1    Funae, O.2    Shimada, A.3
  • 50
    • 52049120711 scopus 로고    scopus 로고
    • Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: A possible role in weight stability?
    • Kusaka I, Nagasaka S, Horie H, Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes Obes Metab. 2008;10(11):1039-1046.
    • (2008) Diabetes Obes Metab , vol.10 , Issue.11 , pp. 1039-1046
    • Kusaka, I.1    Nagasaka, S.2    Horie, H.3    Ishibashi, S.4
  • 51
    • 55449125262 scopus 로고    scopus 로고
    • Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
    • Miyazaki Y, Defronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab. 2008;10(12):1204-1211.
    • (2008) Diabetes Obes Metab , vol.10 , Issue.12 , pp. 1204-1211
    • Miyazaki, Y.1    Defronzo, R.A.2
  • 52
    • 62449169287 scopus 로고    scopus 로고
    • Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study
    • LEAD-2 Study Group
    • Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84-90.
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 84-90
    • Nauck, M.1    Frid, A.2    Hermansen, K.3
  • 53
    • 41749106662 scopus 로고    scopus 로고
    • Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial
    • DOI 10.1111/j.1464-5491.2008.02391.x
    • Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25(4):435-441. (Pubitemid 351490110)
    • (2008) Diabetic Medicine , vol.25 , Issue.4 , pp. 435-441
    • Pan, C.1    Yang, W.2    Barona, J.P.3    Wang, Y.4    Niggli, M.5    Mohideen, P.6    Wang, Y.7    Foley, J.E.8
  • 54
    • 33845489598 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    • Sitagliptin Study 023 Group
    • Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564-2571.
    • (2006) Diabetologia , vol.49 , Issue.11 , pp. 2564-2571
    • Raz, I.1    Hanefeld, M.2    Xu, L.3    Caria, C.4    Williams-Herman, D.5    Khatami, H.6
  • 55
    • 39749184723 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
    • Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(2):537-550.
    • (2008) Curr Med Res Opin , vol.24 , Issue.2 , pp. 537-550
    • Raz, I.1    Chen, Y.2    Wu, M.3
  • 56
    • 2542479374 scopus 로고    scopus 로고
    • Repaglinide versus nateglinide monotherapy: A randomized, multicenter study
    • Repaglinide Versus Nateglinide Comparison Study Group
    • Rosenstock J, Hassman DR, Madder RD, et al; Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care. 2004;27:1265-1270.
    • (2004) Diabetes Care , vol.27 , pp. 1265-1270
    • Rosenstock, J.1    Hassman, D.R.2    Madder, R.D.3
  • 57
    • 33745000699 scopus 로고    scopus 로고
    • Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients
    • Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29(3):554-559. (Pubitemid 44115353)
    • (2006) Diabetes Care , vol.29 , Issue.3 , pp. 554-559
    • Rosenstock, J.1    Sugimoto, D.2    Strange, P.3    Stewart, J.A.4    Soltes-Rak, E.5    Dailey, G.6
  • 58
    • 33751557143 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    • Sitagliptin Study 019 Group
    • Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(10):1556-1568.
    • (2006) Clin Ther , vol.28 , Issue.10 , pp. 1556-1568
    • Rosenstock, J.1    Brazg, R.2    Andryuk, P.J.3    Lu, K.4    Stein, P.5
  • 59
    • 43449096512 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
    • Sitagliptin Study 801 Group
    • Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(10):959-969.
    • (2008) Diabetes Obes Metab , vol.10 , Issue.10 , pp. 959-969
    • Scott, R.1    Loeys, T.2    Davies, M.J.3    Engel, S.S.4
  • 60
    • 22644432754 scopus 로고    scopus 로고
    • Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes
    • Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabet Med. 2005;22(8):980-985.
    • (2005) Diabet Med , vol.22 , Issue.8 , pp. 980-985
    • Yamanouchi, T.1    Sakai, T.2    Igarashi, K.3    Ichiyanagi, K.4    Watanabe, H.5    Kawasaki, T.6
  • 61
    • 36248935637 scopus 로고    scopus 로고
    • Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes
    • DOI 10.1007/s00592-007-0004-9
    • Yilmaz H, Gursoy A, Sahin M, Guvener Demirag N. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetol. 2007;44(4):187-192. (Pubitemid 350132264)
    • (2007) Acta Diabetologica , vol.44 , Issue.4 , pp. 187-192
    • Yilmaz, H.1    Gursoy, A.2    Sahin, M.3    Guvener Demirag, N.4
  • 62
    • 37349008890 scopus 로고    scopus 로고
    • Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
    • Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333-2348.
    • (2007) Clin Ther , vol.29 , Issue.11 , pp. 2333-2348
    • Barnett, A.H.1    Burger, J.2    Johns, D.3
  • 63
    • 74249123519 scopus 로고    scopus 로고
    • Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes
    • Abstract 1239
    • Bergenstal M, Kim T, Trautmann M, Zhuang D, Okerson T, Taylor K. Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes. Circulation. 2008;118:S1086. Abstract 1239.
    • (2008) Circulation , vol.118
    • Bergenstal, M.1    Kim, T.2    Trautmann, M.3    Zhuang, D.4    Okerson, T.5    Taylor, K.6
  • 64
    • 18144401971 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    • DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100.
    • (2005) Diabetes Care , vol.28 , Issue.5 , pp. 1092-1100
    • DeFronzo, R.A.1    Ratner, R.E.2    Han, J.3    Kim, D.D.4    Fineman, M.S.5    Baron, A.D.6
  • 65
    • 53249142132 scopus 로고    scopus 로고
    • Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study
    • DURATION-1 Study Group
    • Drucker DJ, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
    • (2008) Lancet , vol.372 , Issue.9645 , pp. 1240-1250
    • Drucker, D.J.1    Buse, J.B.2    Taylor, K.3
  • 66
    • 48449094712 scopus 로고    scopus 로고
    • Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes
    • Fakhoury W, Lockhart I, Kotchie RW, Aagren M, LeReun C. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Pharmacology. 2008;82(2):156-163.
    • (2008) Pharmacology , vol.82 , Issue.2 , pp. 156-163
    • Fakhoury, W.1    Lockhart, I.2    Kotchie, R.W.3    Aagren, M.4    LeReun, C.5
  • 67
    • 26944477362 scopus 로고    scopus 로고
    • Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial
    • GWAA Study Group
    • Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559-569.
    • (2005) Ann Intern Med , vol.143 , Issue.8 , pp. 559-569
    • Heine, R.J.1    Van Gaal, L.F.2    Johns, D.3    Mihm, M.J.4    Widel, M.H.5    Brodows, R.G.6
  • 68
    • 34247535904 scopus 로고    scopus 로고
    • Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight
    • Karl D, Philis-Tsimikas A, Darsow T, et al. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther. 2007;9(2):191-199.
    • (2007) Diabetes Technol Ther , vol.9 , Issue.2 , pp. 191-199
    • Karl, D.1    Philis-Tsimikas, A.2    Darsow, T.3
  • 69
    • 17144371646 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    • DOI 10.2337/diacare.28.5.1083
    • Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083-1091. (Pubitemid 40616617)
    • (2005) Diabetes Care , vol.28 , Issue.5 , pp. 1083-1091
    • Kendall, D.M.1    Riddle, M.C.2    Rosenstock, J.3    Zhuang, D.4    Kim, D.D.5    Fineman, M.S.6    Baron, A.D.7
  • 70
    • 34249891874 scopus 로고    scopus 로고
    • Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
    • Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487-1493.
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1487-1493
    • Kim, D.1    MacConell, L.2    Zhuang, D.3
  • 71
    • 38549162147 scopus 로고    scopus 로고
    • Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    • Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275-286.
    • (2008) Curr Med Res Opin , vol.24 , Issue.1 , pp. 275-286
    • Klonoff, D.C.1    Buse, J.B.2    Nielsen, L.L.3
  • 72
    • 62449129181 scopus 로고    scopus 로고
    • Liraglutide, a once-daily human GLP1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
    • LEAD-1 SU study group
    • Marre M, Shaw J, Brandle M, et al; LEAD-1 SU study group. Liraglutide, a once-daily human GLP1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(1):268-278.
    • (2009) Diabet Med , vol.26 , Issue.1 , pp. 268-278
    • Marre, M.1    Shaw, J.2    Brandle, M.3
  • 73
    • 34247195226 scopus 로고    scopus 로고
    • A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study
    • Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259-267.
    • (2007) Diabetologia , vol.50 , Issue.2 , pp. 259-267
    • Nauck, M.A.1    Duran, S.2    Kim, D.3
  • 74
    • 36048998480 scopus 로고    scopus 로고
    • Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin
    • DOI 10.2337/dc07-0589
    • Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30(1l):2794-2799. (Pubitemid 350083120)
    • (2007) Diabetes Care , vol.30 , Issue.11 , pp. 2794-2799
    • Riddle, M.1    Frias, J.2    Zhang, B.3    Maier, H.4    Brown, C.5    Lutz, K.6    Kolterman, O.7
  • 75
    • 47649094517 scopus 로고    scopus 로고
    • Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
    • Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;81(2):161-168.
    • (2008) Diabetes Res Clin Pract , vol.81 , Issue.2 , pp. 161-168
    • Seino, Y.1    Rasmussen, M.F.2    Zdravkovic, M.3    Kaku, K.4
  • 76
    • 34249869806 scopus 로고    scopus 로고
    • Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
    • Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608-1610.
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1608-1610
    • Vilsbøll, T.1    Zdravkovic, M.2    Le-Thi, T.3
  • 78
    • 67650066860 scopus 로고    scopus 로고
    • Efficacy and safety of the human GLP1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD)
    • LEAD-4 Study Investigators
    • Zinman B, Gerich J, Buse JB, et al; LEAD-4 Study Investigators. Efficacy and safety of the human GLP1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224-1230.
    • (2009) Diabetes Care , vol.32 , Issue.7 , pp. 1224-1230
    • Zinman, B.1    Gerich, J.2    Buse, J.B.3
  • 79
    • 50149089590 scopus 로고    scopus 로고
    • Evolving concepts of type 2 diabetes management with oral medications: New approaches to an old disease
    • Henry RR. Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. Curr Med Res Opin. 2008;24(8):2189-2202.
    • (2008) Curr Med Res Opin , vol.24 , Issue.8 , pp. 2189-2202
    • Henry, R.R.1
  • 80
    • 34548609993 scopus 로고    scopus 로고
    • Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus
    • Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6): 386-399.
    • (2007) Ann Intern Med , vol.147 , Issue.6 , pp. 386-399
    • Bolen, S.1    Feldman, L.2    Vassy, J.3
  • 81
    • 33845476757 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    • Sitagliptin Study 020 Group
    • Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638-2643.
    • (2006) Diabetes Care , vol.29 , Issue.12 , pp. 2638-2643
    • Charbonnel, B.1    Karasik, A.2    Liu, J.3    Wu, M.4    Meininger, G.5
  • 82
    • 74249123740 scopus 로고    scopus 로고
    • GLP-1 analogues, DPP-IV inhibitors, and the metabolic syndrome
    • Fonseca V, ed. Oxford, UK: Atlas Medical Publishing Ltd
    • Stonehouse AH, Holcombe JH, Kendall DM. GLP-1 analogues, DPP-IV inhibitors, and the metabolic syndrome. In Fonseca V, ed. Therapeutic Strategies: Metabolic Syndrome. Oxford, UK: Atlas Medical Publishing Ltd; 2008:137-157.
    • (2008) Therapeutic Strategies: Metabolic Syndrome , pp. 137-157
    • Stonehouse, A.H.1    Holcombe, J.H.2    Kendall, D.M.3
  • 84
    • 39149145482 scopus 로고    scopus 로고
    • Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004
    • Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol. 2008;18(3):222-229.
    • (2008) Ann Epidemiol , vol.18 , Issue.3 , pp. 222-229
    • Ong, K.L.1    Cheung, B.M.2    Wong, L.Y.3    Wat, N.M.4    Tan, K.C.5    Lam, K.S.6
  • 85
    • 34548118251 scopus 로고    scopus 로고
    • Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy
    • Rubin RR, Peyrot M. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy. Curr Med Res Opin. 2007;23(8):1919-1929.
    • (2007) Curr Med Res Opin , vol.23 , Issue.8 , pp. 1919-1929
    • Rubin, R.R.1    Peyrot, M.2
  • 86
    • 33846083971 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association
    • American Heart Association, American Diabetes Association
    • Buse JB, Ginsberg HN, Bakris GL, et al; American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115(1):114-126.
    • (2007) Circulation , vol.115 , Issue.1 , pp. 114-126
    • Buse, J.B.1    Ginsberg, H.N.2    Bakris, G.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.